To include your compound in the COVID-19 Resource Center, submit it here.

Befar: Phase II data; under review in China

In a placebo-controlled U.S. Phase II study of 161 patients with mild to moderate

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE